Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
The symptoms of Parkinson's disease (PD) reflect disruptions of a number of brain neurotransmitter systems of varying type and degree. Pharmacological agents with multiple neurochemical mechanisms of action are therefore promising candidates for countering these problems and providing comprehensive symptomatic relief for patients. The pharmacological profile of safinamide includes reversible monoamine oxidase B inhibition, blockage of voltage-dependent Na+channels, modulation of Ca2+channels, and inhibition of glutamate release. Safinamide is administered once daily at oral doses of 50-100 mg; it is well-tolerated and safe. Clinical trials have found that it ameliorates motor symptoms when added to established levodopa or single dopamine receptor agonist therapy. The future role of safinamide in PD may be that it enables a reduction in the dosage of dopamine replacement therapies, thereby reducing the adverse effects associated with these treatments. The clinical convenience (once-daily administration), safety, and tolerability of safinamide are better than those of dopamine receptor agonists. The introduction of safinamide reflects a change of approach to drug development for anti-parkinsonian agents in that its broad spectrum of action corresponds to the multiple heterogeneous alterations of brain neurochemistry in PD, rather than being targeted at a single receptor type or neurochemical process. Safinamide is a promising new instrument for the effective symptomatic therapy of PD.
Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Gartenstr. 1, 13088, Berlin, Germany. th.mueller@alexianer.de.
Thomas
T
Müller
Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Gartenstr. 1, 13088, Berlin, Germany.
Paul
P
Foley
D000409:Alanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D000978:Antiparkinson Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001596:Benzylamines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism*
D000978:Antiparkinson Agents; D001596:Benzylamines; D008996:Monoamine Oxidase Inhibitors; C092797:safinamide; D008995:Monoamine Oxidase; D000409:Alanine
Pharmacology. 2013;92(3-4):207-16
24136086
Neuropathol Appl Neurobiol. 2016 Aug;42(5):423-35
26300398
J Clin Psychopharmacol. 1999 Aug;19(4):329-35
10440460
Drugs. 2015 Apr;75(6):705-11
25851099
Pharmacopsychiatry. 1988 May;21(3):144-6
3406051
Exp Neurobiol. 2011 Mar;20(1):1-17
22110357
Expert Rev Neurother. 2002 Nov;2(6):867-76
19810920
BMC Pharmacol. 2011 Feb 21;11:2
21338509
Arch Neurol. 1999 Nov;56(11):1383-6
10555659
FASEB J. 2005 Nov;19(13):1899-901
16148027
J Pharmacol Exp Ther. 1998 May;285(2):397-403
9580576
Eur J Neurol. 1999 Mar;6(2):141-50
10053226
Biopharm Drug Dispos. 2012 Dec;33(9):550-9
23097240
Eur J Neurol. 2013 Feb;20(2):271-80
22967035
Ann Neurol. 2008 Mar;63(3):295-302
18306243
Neurodegener Dis Manag. 2015 Dec;5(6):481-96
26587996
Eur J Pharmacol. 1998 Oct 16;359(1):27-32
9831289
J Neurosci. 2012 Jul 4;32(27):9402-9
22764248
Behav Pharmacol. 1994 Jun;5(3):344-350
11224284
Transl Neurodegener. 2013 Sep 08;2(1):19
24011391
J Neural Transm (Vienna). 2014 Apr;121(4):379-83
24272680
Pharmacol Biochem Behav. 2013 Apr;105:105-11
23360954
J Neural Transm (Vienna). 1997;104(8-9):887-94
9451720
Clin Pharmacol Ther. 2012 Oct;92(4):450-7
22948897
Neurology. 2004 Aug 24;63(4):746-8
15326260
Mov Disord. 2009 Aug 15;24(11):1641-9
19514014
Ann Pharmacother. 2016 Jul;50(7):586-91
27091870
Clin Neuropharmacol. 2007 Sep-Oct;30(5):305-7
17909310
Mov Disord. 2014 Feb;29(2):229-37
24323641
Mov Disord. 2014 Jul;29(8):1028-34
24919813
Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec;384(6):505-15
21850574
Mov Disord. 2015 May;30(6):788-95
25650051
J Neurochem. 2002 Aug;82(4):913-23
12358797
Mov Disord. 2014 Sep;29(10):1273-80
25044402
Neurosci Lett. 2002 Jun 28;326(2):105-8
12057839
Parkinsonism Relat Disord. 2007 Dec;13(8):466-79
17919963
Drugs. 2012 Mar 26;72(5):643-69
22439669
Expert Opin Pharmacother. 2006 Sep;7(13):1715-30
16925499
Pharmacol Res. 2004 Jul;50(1):77-85
15082032
Curr Med Chem. 2004 Aug;11(15):2033-43
15279566
Neuropsychopharmacology. 2007 May;32(5):1011-20
17063156
Eur J Pharmacol. 1989 Aug 3;166(3):589-90
2680528
Neurol Res. 2008 May;30(4):417-9
18237459
J Med Chem. 2007 Nov 15;50(23):5848-52
17915852
Mov Disord. 2012 Jan;27(1):106-12
21913224
Curr Top Med Chem. 2005;5(1):15-30
15638775
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S34-7
20083003
Mov Disord. 2010 Mar 15;25(4):508-10
20014061
Clin Pharmacol Drug Dev. 2013 Jan;2(1):79-89
27121562
Biol Psychiatry. 2009 Dec 1;66(11):997-1004
19699472
Parkinsonism Relat Disord. 2013 May;19(5):508-14
23402994
Clin Neuropharmacol. 1999 Sep-Oct;22(5):273-6
10516877